pdufa.bio
HomeReadouts › October 2027

October 2027 clinical-trial readouts

Updated ·next FDA decision on the calendar
trial-readout estimates for October 2027, each row linked to its primary source. Readout dates are estimated primary-completion windows from ClinicalTrials.gov and shift.
← September 2027November 2027 →
7 readouts
LLY · Oct 2027 (est.)
Tirzepatide: Obesity
OGN · Oct 2027 (est.)
150μg CFA (Elonva®) at stimulation day (SD) 1 and 100μg CFA(Elonva®) at SD 5: Esophagogastric Adenocarcinoma
Awaiting data
ONC · Oct 2027 (est.)
Zanubrutinib: Primary Membranous Nephropathy
TARS · Oct 2027 (est.)
TP-03: Lyme Disease
Awaiting data
MRK · Oct 2027 (est.)
MK-8527: Human Immunodeficiency Virus (HIV)
ONC · Oct 2027 (est.)
Tislelizumab: Metastatic Gastric Adenocarcinoma
TLX · Oct 2027 (est.)
177Lu-TLX591: Advanced Cancer
Looking for an approval probability for these? We deliberately don't publish one. Here's why, and what we show instead (verified history + base rates).